Posted: Mon Sep 14, 2009 9:20 am Post subject: NexBio Inc.'s new drug Fludase may resist mutations
13 Sep 2009 20:23:17 GMT
Tests in mice and in lab dishes show that NexBio Inc.'s drug Fludase (DAS181) can stop the seasonal influenza virus from infecting cells and can fight strains of virus that have evolved resistance to Tamiflu. Extensive, prolonged nonclinical influenza studies have not shown the development of any meaningful resistance.
Fludase affects the human cells that influenza infects, not the virus itself and that should make it less likely to cause the virus to develop resistance, company spokesman Dr. David Wurtman said.
It affects the sialic acid receptor -- the molecular doorway that flu viruses use to attach to cells, he said.
"It makes it impossible to spread, so it can't infect neighboring cells," Wurtman said in a telephone interview.... we are moving forward with our ongoing clinical development of DAS181... _________________ https://twitter.com/mixin1771
You cannot post new topics in this forum You cannot reply to topics in this forum You cannot edit your posts in this forum You cannot delete your posts in this forum You cannot vote in polls in this forum